new options for hf “drugs & devices”
TRANSCRIPT
![Page 1: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/1.jpg)
Michael Zacharias, D.O., F.A.C.C.Assistant Professor of Medicine
Section of Heart Failure and Heart TransplantationMedical Director of Mechanical Circulatory Support (MCS)
Assistant Program Director Advanced Heart Failure/Transplant Fellowship
New Options for HF“Drugs & Devices”
March 20, 2021
![Page 2: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/2.jpg)
New Options for HF “Drugs and Devices”
Michael Zacharias DO, Cardiologist, UH Harrington Heart & Vascular Institute, Assistant Professor of Medicine, Case Western Reserve University School of Medicine
Disclosures:Commercial Support / Sponsorship: None
Conflict of Interest: None
![Page 3: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/3.jpg)
Overview
• Case
• Background of HF
• Advances in heart failure management• Medications• Devices
• Revisit the case
• When to refer to AHF
3
![Page 4: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/4.jpg)
Overview
• Case
• Background of HF
• Advances in heart failure management• Medications• Devices
• Revisit the case
• When to refer to AHF
4
![Page 5: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/5.jpg)
Case• 58M
– CAD/MI w/prior remote PCI– Ischemic cardiomyopathy (LVEF 30%)– Primary prevention ICD
• Hospitalized three times in the last year for ADHF• Not able to “enjoy life” because of SOB• Also has noted worsening LE edema and has been
sleeping in his recliner to “breath easier”
5
![Page 6: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/6.jpg)
Case
• Medications– Metoprolol succinate 100 mg daily– Lisinopril 10 mg daily– Furosemide 80 mg twice a day– ASA 81 mg daily– Atorvastatin 80 mg daily
6
![Page 7: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/7.jpg)
Case
• Labs:– Na: 132– Cr 1.6
• Repeat echo shows LVEF 25-30% with worsening MR and further dilatation of his left ventricle
7
![Page 8: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/8.jpg)
Case
• Despite adjustments in diuretic therapy he continues to retain fluid with evidence of worsening renal function
• He has a resting HR of 75 and SBP 115
• He is referred to the Heart Failure clinic looking for help
8
![Page 9: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/9.jpg)
Questions to consider
• Why is he failing medical therapy?
• Can we optimize his medical therapy?
• Aside from medication, is there anything else we can pursue to help guide his management?
• When should we consider advanced heart failure therapies?
9
![Page 10: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/10.jpg)
Overview
• Case
• Background of HF
• Advances in heart failure management• Medications• Devices
• Revisit the case
• When to refer to AHF
10
![Page 11: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/11.jpg)
Background
• Growing prevalence of heart failure– Currently 5.7 million Americans– Estimated to grow to >30 million by 2030– Only form of heart disease increasing in
prevalence
11
Circ Heart Fail. 2013;6(3):606-619.
![Page 12: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/12.jpg)
Background
• Most common cause of hospitalization– Primary diagnosis in >1 million discharges per
year– Affects 10% of men, 8% women over age 60– 30-Day readmission rate 20-25%– Of those hospitalized:
–HFrEF: 53% –HFpEF: 47%
12
Circ Heart Fail. 2013;6(3):606-619.
![Page 13: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/13.jpg)
Background
• Why?– Increasing prevalence of risk factors– Improved survival post-MI– Aging population
13
Circ Heart Fail. 2013;6(3):606-619.
![Page 14: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/14.jpg)
Background
Mortality of patients hospitalized for AHF• 10% within 30 days• 22% within 1 year• 42% within 5 years
• Higher 5-year mortality rate than many cancers including leukemia, lymphoma, colon, or breast
14
Circ Heart Fail. 2012;5(4):414-421.JAMA. 2004;292(3):344-350.http://seer.cancer.gov/statfacts.
![Page 15: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/15.jpg)
HF Therapy Timeline
15
1980s 1990s 2000s 2010-PresentPre-1980s
DiureticsDigitalis
ACEi β-blockerICD
CRTARBMRALVAD
Pressure monitorARNIFunny channel (If)SGLT2 inhibitors
![Page 16: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/16.jpg)
16
Circulation. 2001;104:2996-3007
![Page 17: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/17.jpg)
17
N Engl J Med 2003; 348:2007-2018
![Page 18: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/18.jpg)
Overview
• Case
• Background of HF
• Advances in heart failure management• Medications• Devices
• Revisit the case
• When to refer to AHF
18
![Page 19: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/19.jpg)
Advances in Heart Failure Management
• Medications– Neprolysin inhibition– Heart rate modulation via funny channel (If)– Sodium-glucose co-transporter-2 (SGLT2) inhibitors
• Devices– Pulmonary arterial pressure monitoring system – Left ventricular assist device (LVAD)
19
![Page 20: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/20.jpg)
Sacubitril/Valsartan
•Formerly “LCZ-696” now Entresto®
•ARNi• Angiotensin Receptor-Neprilysin Inhibitor
•PARADIGM-HF Trial (NEJM 2014)
•PARAGON-HF Trial (NEJM 2019)
![Page 21: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/21.jpg)
Sacubitril/Valsartan
21
JACC HF 2014
![Page 22: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/22.jpg)
•NYHA class II-IV and LVEF <40%
•8442 pts
•LCZ 696 (200 mg bid) vs Enalapril (10 mg bid)
•Mean duration of follow up: 27 months
•Primary outcome: CV death or first HF hospitalization
![Page 23: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/23.jpg)
NEJM 2014
![Page 24: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/24.jpg)
NEJM 2014
![Page 25: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/25.jpg)
25
•NYHA class II-IV and LVEF >45%•4822 pts•Entresto (97/103 mg bid) vs Valsartan (160 mg bid)•Mean duration of follow up: 4 years•Primary outcome: total hospitalizations for HF and death from CV causes
![Page 26: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/26.jpg)
26
2/2021: Entresto approved for HFpEF. FDA “Benefits are most clearly evident in patients with LVEF below normal (45-57%)”
![Page 27: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/27.jpg)
Heart rate modulation
27
Framingham Data
Am Heart J.1993;125:1148-1154
• Heart rate is determined by spontaneous electrical pacemaker activity in the sinoatrial node controlled by the If current
• Prior data indicates that increasing HR is associated with worsened cardiac outcomes
• Recent literature supports that a HR <70 may be beneficial in pts with HFrEF
![Page 28: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/28.jpg)
Heart rate modulation
28
Lancet 2008
•LVEF <40% and stable CAD
•5438 pts
•HR >70 vs <70
•Cardiovascular outcomes
![Page 29: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/29.jpg)
29
Lancet 2008
HR >70:34% increased risk of CV death 53% increase in heart failure hospitalizations
Lancet 2008
![Page 30: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/30.jpg)
Ivabradine (Corlanor®)
• Selectively blocks funny current (If)– Reduces slope of diastolic
repolarization reducing HR• Independent effect of β-blocker
• No effect on blood pressure
• No negative inotropic, lusitropic, or contractility effects
30
Curr Med Res Opin. 2005
![Page 31: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/31.jpg)
•Symptomatic heart failure, LVEF <35%, hospitalized within the last year, SR with HR >70 bpm on stable beta blocker
•6558 pts
•Mean duration of follow up: 22.9 months
•Primary outcome: CV death or HF hospitalization
Lancet 2010
![Page 32: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/32.jpg)
Lancet 2010
![Page 33: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/33.jpg)
Lancet 2010
18% reduction in primary endpoint (CV death or HF hospitalization)26% reduction in HF death or hospitalization
![Page 34: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/34.jpg)
DM Drug Trials
• Meta-analysis of 42 trials of Rosiglitazone suggested increased risks of both MI and CV mortality
• 2008: FDA requires diabetic trials to assess CV risk
34
![Page 35: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/35.jpg)
CVOT
35
Cochrane UK
![Page 36: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/36.jpg)
36
SGLT2
![Page 37: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/37.jpg)
37
•NYHA class II-IV and LVEF <40%•4744 pts (with/without DM)•Dapagliflozin (10 mg daily) vs Placebo•Mean duration of follow up: 18 months•Primary outcome: worsening HF or CV death
![Page 38: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/38.jpg)
38
![Page 39: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/39.jpg)
39
Cardiovascular Diabetology 2019
![Page 40: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/40.jpg)
Why we do what we do
40
![Page 41: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/41.jpg)
Key Points for Med Mgt of HFrEF
• RAAS and sympathetic systems are the enemy– There is no such thing as “low” blood pressure,
unless the patient is symptomatic. • If symptomatic, think:
– Hypovolemia– RV dysfunction/failure– Advanced/stage D HF
• Minimize loop diuretics to maximize vasodilator, MRA, SGLT2
41
![Page 42: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/42.jpg)
Devices
42
![Page 43: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/43.jpg)
Symptoms are late in the game
43
![Page 44: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/44.jpg)
CardioMEMs®
• Continuous monitoring
• RHC
• Implanted into left PA
• No battery/replacement
• Remote monitoring
44
![Page 45: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/45.jpg)
CardioMEMs
45
![Page 46: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/46.jpg)
•NYHA class III for at least 3 months, no LVEF cutoff, and hospitalized within the last year for HF
•550 pts implanted– 270 randomized to treatment– 280 pts randomized to control group– Post-procedure medication
• prior anticoagulants resumed• otherwise ASA 81 + Clopidogrel 75 x30 days, then ASA 81
alone
•Mean duration of follow up: 15 months
Lancet 2011
![Page 47: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/47.jpg)
Lancet 2011
• 28% reduction in HF hospitalizations within the first 6 months and 37% by 15 months
• Improved QOL• Treatment group required <1
medication adjustment per patient per month vs. control
• No PE or pulm infarct during study time
![Page 48: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/48.jpg)
Left ventricular assist device (LVAD)
48
• Intra-corporeal pump• 1st generation: pulsatile• 2nd/3rd generation: continuous• Axial or Centrifugal pump• Constant power source• Antiplatelet/anticoagulant
![Page 49: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/49.jpg)
49
ISHLTJHLT. 2017.
~2500-3000/yr
![Page 50: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/50.jpg)
50
NEJM 2001
• 129 patients with NYHA IV, stage D HF who were ineligible for cardiac transplantation
• Primary endpoint: death from any cause
![Page 51: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/51.jpg)
51
![Page 52: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/52.jpg)
52
NEJM. 2009.
![Page 53: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/53.jpg)
LVAD Thrombosis
53AJMedSci. 2015.NEJM. 2014.
![Page 54: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/54.jpg)
54
NEJM. 2017.
• Investigate the effectiveness of a new magnetically levitated centrifugal continuous-flow pump that was engineered to avert thrombosis.
• 294 patients, 152 were assigned to the centrifugal-flow pump group and 142 to the axial-flow pump group
![Page 55: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/55.jpg)
HeartMate 3TM LVAD
• Fully magnetically levitated
• Larger gaps in pump housing
• Built-in pulsatility
55
![Page 56: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/56.jpg)
RR (95%CI) = 0.21 (0.11 – 0.38)P<0.0001
HeartMate 3(N=515)
HeartMate II(N=505)
Significantly lower rate of pump replacement at 2 years
Only 3 HeartMate 3™ LVAD exchanges for suspected pump
thrombosis or elevated LDH
![Page 57: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/57.jpg)
57
![Page 58: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/58.jpg)
Current FDA Approved Durable MCS
58
HeartMate IITM LVAD Total Artificial Heart (TAH)
• BTT• DT
• BTT• DT
• BTT
HeartMate 3TM LVAD
• BTT• DT
Heartware HVADTM
![Page 59: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/59.jpg)
Overview
• Case
• Background of HF
• Advances in heart failure management• Medications• Devices
• Revisit the case
• When to refer to AHF
59
![Page 60: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/60.jpg)
Case
• Worsening symptoms
• Multiple hospitalizations in last year
• Worsening LV function/MR
• Cardio-renal
• Hyponatremia
60
![Page 61: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/61.jpg)
Case
• Identify reasons for worsening symptoms • Medication optimization
– Transition to ARNi– Add MRA– Uptitrate beta blocker (once euvolemic)– Ivabradine (after uptitration of β-B, if needed)– Initiate SGLT2
• Consider device therapy (CardioMEMs) • For persistent symptoms; refer for Advanced Therapies
61
![Page 62: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/62.jpg)
Patients with any of the following should be referred for evaluation for advanced heart failure therapies1
Reference: 1. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Yancy CW, Januzzi JL Jr, Allen LA, Butler J, Davis LL, Fonarow GC, et al. J Am Coll Cardiol. 2018 Jan 16;71(2):201-230.
I IV inotropesN NYHA IIIB/IV or persistently elevated natriuretic peptidesE End-organ dysfunction (Cr > 1.8 mg/dL or BUN > 43 mg/dL)E Ejection fraction ≤ 35%D Defibrillator shocksH Hospitalizations > 1E Edema (or elevated PA pressure) despite escalating diureticsL Low blood pressure, high heart rateP Prognostic medication — progressive intolerance or down-titration
GDMT
Additional patient considerations for referral:• CRT non-responder• Physical activity limited or impaired quality of life
62
I NEED HELP
![Page 63: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/63.jpg)
When to refer
63
“SHARK”
![Page 64: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/64.jpg)
When to refer
• S odium (hyponatremia Na<136)
• H ospitalizations • readmit in 30 days or ≥ 2 hospital stays in 6 months
• A rrhythmias (atrial/ventricular)
• R efractory to meds (ACE/ARB/BB)
• K idney failure (Cr ≥1.2, or >0.3 from b/l)
64
![Page 65: New Options for HF “Drugs & Devices”](https://reader035.vdocuments.mx/reader035/viewer/2022070414/62c0b382c79a067f9e15c7d1/html5/thumbnails/65.jpg)
In conclusion
• New therapies (both medical and device) are reshaping the landscape of HF management
• Given the limitations of transplant, LVAD therapy has continued to improve and now provides a viable alternative as either a bridge or permanent treatment
65